Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body’s immune system in the fight against cancer, today announced a collaboration with Urology Centers of Alabama (UCA) in the Cchek™ early prostate cancer detection study.
SAN JOSE, Calif., Nov. 22, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body’s immune system in the fight against cancer, today announced a collaboration with Urology Centers of Alabama (UCA) in the Cchek™ early prostate cancer detection study. UCA will provide patient samples in Anixa’s ongoing study, including support of clinical validation of Anixa’s Cchek™ Prostate Cancer Confirmation test. UCA is one of several sites across the U.S. participating in this study. Dr. Charles Edward Bugg, Jr. will serve as the Principal Investigator at UCA. Amit Kumar, Ph.D., Chief Executive Officer of Anixa, stated, “We are pleased to have another highly regarded urology practice join our team of collaboration partners. We look forward to UCA’s participation as we continue the clinical validation phase of the Cchek™ Prostate Cancer Confirmation test in preparation for commercial launch later this year.” About Cchek™ Urology Centers of Alabama About Anixa Biosciences, Inc. Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa’s current expectations concerning future events and results. We generally use the words “believes,” “expects,” “intends,” “plans,” “anticipates,” “likely,” “will” and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in “Item 1A - Risk Factors” and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. Anixa contact: Tiberend Strategic Advisors, Inc. Miriam Miller (Investors) Johanna Bennett (Media)
View original content to download multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-announces-collaboration-with-urology-centers-of-alabama-on-cchek-prostate-cancer-study-300963557.html SOURCE Anixa Biosciences, Inc. | ||
Company Codes: NASDAQ-NMS:ANIX |